TD Asset Management Inc. acquired a new stake in Loxo Oncology, Inc. (NASDAQ:LOXO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 9,710 shares of the biopharmaceutical company’s stock, valued at approximately $779,000.

Other large investors also recently bought and sold shares of the company. Legal & General Group Plc raised its stake in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 284 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Loxo Oncology by 162.6% in the first quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 5,063 shares during the last quarter. American International Group Inc. raised its stake in shares of Loxo Oncology by 27.1% in the first quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 2,081 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the last quarter.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at 77.76 on Wednesday. Loxo Oncology, Inc. has a 12 month low of $17.14 and a 12 month high of $83.12. The stock’s market cap is $2.32 billion. The stock’s 50 day moving average price is $73.71 and its 200-day moving average price is $57.32.

Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by $0.15. During the same period in the prior year, the business posted ($0.77) EPS. Equities analysts expect that Loxo Oncology, Inc. will post ($4.53) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/9710-shares-in-loxo-oncology-inc-loxo-acquired-by-td-asset-management-inc.html.

A number of equities research analysts have issued reports on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Ifs Securities reiterated an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Finally, JMP Securities lowered Loxo Oncology from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $83.12 to $17.14 in a research note on Tuesday. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Loxo Oncology has a consensus rating of “Buy” and a consensus price target of $70.73.

In other Loxo Oncology news, Director Lori Anne Kunkel sold 10,000 shares of Loxo Oncology stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $75.17, for a total transaction of $751,700.00. Following the completion of the transaction, the director now owns 16,840 shares in the company, valued at $1,265,862.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Keith T. Flaherty sold 7,250 shares of Loxo Oncology stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $72.26, for a total transaction of $523,885.00. Following the transaction, the director now owns 20,432 shares of the company’s stock, valued at approximately $1,476,416.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,073 shares of company stock valued at $3,397,662. 27.80% of the stock is currently owned by company insiders.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.